Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Payables (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Payables data on record, last reported at $8.0 million in Q1 2025.

  • For Q1 2025, Payables rose 349.63% year-over-year to $8.0 million; the TTM value through Mar 2025 reached $8.0 million, up 349.63%, while the annual FY2025 figure was $8.0 million, 349.63% up from the prior year.
  • Payables reached $8.0 million in Q1 2025 per SXTC's latest filing, up from $1.8 million in the prior quarter.
  • Across five years, Payables topped out at $8.0 million in Q1 2025 and bottomed at $1.5 million in Q1 2023.
  • Average Payables over 5 years is $3.6 million, with a median of $3.0 million recorded in 2021.
  • Peak YoY movement for Payables: tumbled 56.22% in 2023, then soared 349.63% in 2025.
  • A 5-year view of Payables shows it stood at $3.0 million in 2021, then rose by 15.84% to $3.5 million in 2022, then crashed by 56.22% to $1.5 million in 2023, then increased by 14.71% to $1.8 million in 2024, then skyrocketed by 349.63% to $8.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $8.0 million in Q1 2025, $1.8 million in Q1 2024, and $1.5 million in Q1 2023.